Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer

$11.5bn Acquisition Values Firm At A 34%-38% Premium

Executive Summary

Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.

You may also be interested in...



Value Of BioPharma M&A Leaps in Q3

Merck & Co's proposed acquisition of Acceleron and a couple of big purchases from Sanofi drove up the value of the sector's M&A activities, according to the latest report from Biomedtracker

Merck Forecasts Global Molnupiravir Revenues Of $5bn-$7bn Through 2022

Assuming emergency use authorization of the antiviral to fight COVID-19 in December, Merck expects to make $500m-$1bn this year. It will share profits equally with partner Ridgeback.

Acceleron To Be Next M&A Target With Rumored $11bn Deal

The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel